AI and Medical Technology company Echo IQ (ASX:EIQ) has launched its cloud-based enhanced screening platform for structural heart disease, commencing with aortic stenosis , and it is now available to registered customers in the US.
The platform will be sold under the name EchoSolv which has been chosen to reflect the importance of identifying patients at risk of structural heart disease, and the vital role that analysis of echocardiograms plays in meeting that challenge.
The EchoSolv software platform is designed to support clinicians and physicians in identifying patients with guideline-defined aortic stenosis in the first instance. Whilst treatment options for sufferers of severe aortic stenosis are considered safe and reliable, the condition has a two-year mortality rate of 50% when left untreated. EchoSolv is designed to ensure patients who would benefit from treatment or further clinical review are accurately identified.
The rigorously tested product has been developed in consultation with leading cardiologists. Echo IQ’s Chief Medical Advisor and Cardiologist, Professor David Playford indicates that EchoSolv “automates the identification of high-risk aortic stenosis patients. It heralds the beginning of a new era by improving the cardiologist’s focus on patients at-risk without requiring any change of cardiac imaging solution, no new hardware, no new devices, and no new interference with existing infrastructure.”
Echo IQ is initially introducing EchoSolv in the United States where thecompany has recently achieved positive results with the product in a clinical efficacy study with Harvard Medical School’s Beth Israel Deaconess Medical Center. This study demonstrated that EchoSolv successfully identified sizeable cohorts of patients with guideline-detected severe aortic stenosis as well those with a significantly heightened risk of death from the condition.
Echo IQ is launching EchoSolv with two pricing models.
A price-per-assessment model will see customers conducting retrospective reviews charged for any records evaluated. For those customers integrating EchoSolv into real-time clinical workflows for immediate patient assessments, a flat monthly SaaS fee will be charged.
The launch of EchoSolv gives healthcare professionals a powerful new decision-support tool to help identify patients who might benefit from proven therapies for severe aortic stenosis. Whether used retrospectively to assess existing records or integrated into real-time clinical workflows, clinicians now have access to an additional layer of assessment in support of more effective patient care,” Echo IQ Chief Commercial Officer Deon Strydom said.
“We are pleased to be taking this important step in the US where a number of significant milestones have been met. Our experienced and highly regarded healthcare executive Don Fowler is already engaging with several leading hospitals, ASCs and health systems in leading US cardiology markets from his base in Austin, TX and we expect to be seeing EchoSolv deployed with a number of these at pace.
“Looking further ahead, we look forward to incorporating new features, capabilities, and additional conditions beyond aortic stenosis into EchoSolv – many of which are currently in development.”